What is Smith & Nephew's gross profit margin?

What factors drove the changes in Smith & Nephew's revenue and profit?

What is the revenue and EPS growth rate for Smith & Nephew year over year?

What is the market's earnings forecast for Smith & Nephew next quarter?

What is Smith & Nephew's latest dividend and current dividend yield?

What guidance did Smith & Nephew's management provide for the next earnings period?

What were the key takeaways from Smith & Nephew's earnings call?

What were the key takeaways from Smith & Nephew’s earnings call?

- **2025 Strong Finish**: 5.3% revenue growth, 19.7% margin, $840M free cash flow, and $500M buyback.
- **2026 Growth Drivers**: 6% revenue, 8% profit growth, LANDMARK launch, and Integrity integration.
- **China Headwinds**: Joint Repair VBP annualized, 2026 AET/ENT VBP impact limited to $15-20M profit.
- **Robotics Expansion**: CORI Shoulder placements expected to accelerate in ASCs.
- **Innovation Pipeline**: 16 new products in 2026, including TESSA spatial surgery platform.

**【CEO Summary Section】**
- Reported 5.3% underlying revenue growth for 2025, with all three business units exceeding 5% growth.
- Delivered 160bps margin expansion to 19.7%, driven by cost savings and operational efficiency.
- Acquired Integrity Orthopaedics for $450M, targeting shoulder biomechanical repair market.
- 2026 guidance: 6% organic revenue growth, 8% trading profit growth, and $800M free cash flow.

**【CFO Financial Commentary】**
- Q4 2025 revenue: $1.7B (6.2% underlying growth), with broad-based growth across regions.
- Trading profit: $1.2B (160bps margin expansion), supported by $280M cumulative cost savings.
- Free cash flow: $840M (52.5% YoY growth), enabling $500M share buyback.
- 2026 outlook: $1.3B trading profit (including Integrity dilution), 10%+ ROIC.

**【Q&A Key Highlights】**
- **Revenue Phasing**: Q1 2026 softer (4.5-5% growth), Q2-Q4 stronger (7.5-8% growth) due to LANDMARK launch.
- **China Impact**: Joint Repair VBP fully annualized, 2026 AET/ENT VBP headwinds limited to $15-20M profit impact.
- **LANDMARK Knee**: Cementless launch Q3 2026, cemented Q1 2027, targeting ASC efficiency and market share.
- **Integrity Integration**: TENDON SEAM expected to scale post-2028, complementing REGENETEN biologics leadership.
- **Skin Subs Market**: CMS reimbursement changes causing short-term volume softness, but long-term growth in surgical channels.


Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript

- **Revenue Momentum**: 6.7% Q2 growth, U.S. up 8.7%, emerging markets (ex-China) +12.2%.
- **Margin Expansion**: 100 bps H1 trading margin improvement, targeting 19%-20% full year.
- **Share Buyback**: $500M announced for H2, funded by free cash flow.
- **Tariff Mitigation**: 2/3 Ortho production in U.S., limiting impact to $15-$20M.
- **Innovation Driven Growth**: 75% H1 revenue from products launched in last 5 years.
- **Risks**: CMS skin sub reimbursement proposal could impact 2026 Wound margins.

**【CEO Summary Section】**
- **Revenue Growth**: 6.7% underlying growth in Q2 2025, driven by sequential acceleration across all regions and business units. U.S. revenue grew 8.7%, while emerging markets (excluding China) expanded 12.2%.
- **Business Unit Performance**: 
  - **Orthopaedics**: 5.5% growth, with U.S. Recon and Robotics improving for the fourth consecutive quarter. Global Knees and Hips grew 2.9% and 3.4%, respectively.
  - **Sports Medicine**: 5.7% growth, with Joint Repair (excluding China) up 13.7% due to Q-FIX and REGENETEN adoption.
  - **Advanced Wound Management**: 10.2% growth, driven by Bioactives rebound and PICO device sales.
- **Profitability**: Trading margin expanded 100 bps to 17.7%, with $500 million share buyback announced for H2 2025.
- **Innovation**: Launches include TRIGEN MAX tibia nail, CORIOGRAPH shoulder planning, and REGENETEN hip repair expansion.

**【CFO Financial Commentary】**
- **Revenue**: $3 billion in H1, 5% underlying growth. Q2 reported revenue $1.6 billion, 7.8% growth with 110 bps FX tailwind.
- **Gross Margin**: 70.5%, up 40 bps vs. prior year, driven by price/volume leverage and operational savings.
- **Operating Expenses**: 60 bps positive leverage, with $50 million savings brought forward to H1.
- **Trading Profit**: $523 million (17.7% margin), up 11.2%. Full year margin guidance 19%-20%.
- **Cash Flow**: $244 million free cash flow in H1, targeting >$600 million for 2025.
- **Tariffs**: Expected $15-$20 million headwind, primarily in H2.

**【Q&A Highlights】**
- **Revenue Guidance**: Maintained 5% full year target despite Q2 strength, citing macro uncertainty and tough Q4 2024 comp.
- **Margin Expansion**: 200 bps+ expected in H2, driven by manufacturing savings and reduced China VBP impact.
- **U.S. Knees**: Softness due to surgeon transitions and portfolio rationalization, but hips growth offset weakness.
- **Tariffs**: No Nairobi protocol use yet; 2/3 of Ortho production in U.S., mitigating impact.
- **Buyback**: Funded by free cash flow, with leverage expected below 2x by year-end.
- **Skin Subs**: CMS proposal could reduce 2026 Wound sales and margins, but long-term focus on evidence-based products.
- **M&A**: Active pipeline, with bolt-ons prioritized over buyback.

Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: 5.3% 2024 growth, 8.3% Q4, with U.S. Recon on track to match market by end-2025.
- **Margin Expansion**: 19-20% 2025 trading margin, driven by $325-375M cost savings and operational leverage.
- **China Headwinds**: 150bps 2025 impact from VBP, but Robotics and AET growth offsetting.
- **Innovation Pipeline**: >60% of growth from new products, with AETOS Shoulder, CATALYSTEM, and CORI leading.
- **Free Cash Flow**: Targeting >$600M in 2025, up from $551M in 2024.
- **ROIC**: To exceed cost of capital in 2025, with Ortho ROIC doubling.

**【CEO Summary Section】**
- Delivered 5.3% underlying revenue growth in 2024, driven by successive waves of innovation and operational improvements under the 12-Point Plan.
- 8.3% Q4 growth, with 8.1% excluding China, reflecting strong U.S. performance and surgical business benefits from two extra trading days.
- 2025 guidance: ~5% revenue growth, 19-20% trading margin expansion, with significant savings from manufacturing network optimization.
- China headwinds cost 280bps of Q4 group growth, with 150bps full-year 2025 impact, primarily from VBP in Ortho and Sports Medicine.
- U.S. Recon on track to grow in line with market by end-2025, supported by product availability and commercial execution.
- Innovation pipeline: >60% of 2024 growth from products launched in last five years, with AETOS Shoulder, CATALYSTEM, and CORI robotics driving future growth.

**【CFO Financial Commentary】**
- 2024 full-year revenue: $5.8B (5.3% underlying growth), with 60bps trading margin expansion to 18.1%.
- Q4 GAAP net income: $420M, Non-GAAP EPS: $1.08 (vs. $0.95 prior year).
- 2025 outlook: 19-20% trading margin, driven by $325-375M cost savings (e.g., $239M annualized from 12-Point Plan), offsetting 100bps China VBP headwinds.
- Free cash flow: $551M in 2024, targeting >$600M in 2025 with lower restructuring costs ($45M vs. $123M prior year).
- ROIC to exceed cost of capital in 2025, with Ortho ROIC doubling to ~15%.

**【Q&A Key Points】**
- **China Risks**: 2025 guidance includes 150bps headwind, with Q1 softness in Recon and Sports VBP. Long-term strategy focuses on Robotics and AET, despite local competition.
- **U.S. Growth**: Ortho ADS growth to 2-3% in Q1, accelerating to 3-4% by year-end, driven by CATALYSTEM and CORI adoption.
- **R&D Spending**: 2024 R&D down 4% YoY due to EU MDR roll-off, but innovation pipeline remains strong (60%+ growth from new products).
- **Inventory Management**: DSI improved 23 days in 2024, with focus on SKU rationalization and ZBB cost savings flowing into 2025 P&L.
- **Tariff Risks**: Minimal impact on U.S. business (most products made domestically), but Wound segment exposed to China tariffs.
- **Robotics Momentum**: CORI installed base >1,000 units, with shoulder expansion and video-based navigation launch in 2025.

Actual																								1.14
Forecast																								1.155
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.30%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	2.57B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	3.18B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-19.06%

SNN

SNN fundamentals

SNN Q4 2025 Earnings

Earnings Call

You can ask Aime

SNN

SNN fundamentals

SNN Q4 2025 Earnings

Earnings Call

SNN Earnings Call Summary for Q4/20253:30 AM on Mar 2, 2026

SNN Earnings Call Summary for Q2/20253:30 AM on Aug 5, 2025

SNN Earnings Call Summary for Q4/2024Invalid Date on Feb 25, 2025

SNN Earnings Call Summary for Q3/2024 Apr 2, 2026

SNN Earnings Call Summary for Q2/2024 Apr 2, 2026

You can ask Aime